Knott David M Jr
Reported holdings as of Q2 2026, from 19 quarterly filings.
This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
Download these holdings as CSV
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ALPHABET INC | GOOG | $32.3M | 91,420 | +1.47pp | 19q | HELD | |
| APOLLO GLOBAL MGMT INC | APO | $26.6M | 225,000 | -0.85pp | 13q | HELD | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $9.6M | 437,245 | -0.81pp | 10q | +3.6%+$333.3K | |
| XERIS BIOPHARMA HOLDINGS INC | XERS | $8.4M | 1,060,000 | +0.78pp | 11q | HELD | |
| TRAVERE THERAPEUTICS INC | TVTX | $8.4M | 147,282 | +1.94pp | 12q | +4.7%+$377.7K | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $7.7M | 63,000 | +0.13pp | 12q | HELD | |
| BRIDGEBIO PHARMA INC | BBIO | $6.9M | 92,850 | -0.32pp | 5q | +3.2%+$212.3K | |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | $6.7M | 1,600,000 | +0.18pp | 2q | HELD | |
| ALKERMES PLC | ALKS | $6.4M | 121,759 | +0.85pp | 5q | +1.5%+$92.2K | |
| JPMORGAN CHASE & CO | JPM | $5.9M | 18,098 | -0.28pp | 19q | -7.1%-$451.4K | |
| JANUS DETROIT STR TR | JAAA | $4.7M | 93,528 | -0.31pp | 12q | HELD | |
| LPL Financial Holdings Inc. UNVERIFIED ID | $4.6M | 16,500 | -0.50pp | 2q | HELD | ||
| COGENT BIOSCIENCES INC | COGT | $4.3M | 111,081 | -0.11pp | 3q | +6.8%+$274.0K | |
| TG THERAPEUTICS INC | TGTX | $3.7M | 66,839 | +0.16pp | 3q | -25.7%-$1.3M | |
| CATALYST BANCORP INC | CLST | $3.6M | 114,000 | - | new | NEW | |
| AGIOS PHARMACEUTICALS INC | AGIO | $3.5M | 95,058 | -0.01pp | 3q | +2.1%+$74.2K | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $3.3M | 181,000 | -0.35pp | 7q | HELD | |
| RELMADA THERAPEUTICS INC | RLMD | $3.1M | 451,000 | -0.17pp | 2q | +2.7%+$81.0K | |
| ARCUS BIOSCIENCES INC | RCUS | $2.5M | 81,241 | +0.28pp | 6q | HELD | |
| CYBIN INC | HELP | $2.4M | 370,000 | +0.29pp | 7q | +5.7%+$132.2K | |
| SPDR SERIES TRUST | XBI | $2.4M | 15,000 | +0.11pp | 11q | HELD | |
| REZOLUTE INC | RZLT | $1.9M | 370,000 | +0.35pp | 4q | HELD | |
| ALLIANCEBERNSTEIN HLDG L P | AB | $1.7M | 48,000 | -0.18pp | 19q | HELD | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $1.6M | 3,000 | +0.23pp | 5q | +50.0%+$537.0K | |
| ATRICURE INC | ATRC | $1.4M | 51,400 | -0.11pp | 6q | HELD | |
| DOCGO INC | DCGO | $1.4M | 2,670,850 | -0.27pp | 19q | HELD | |
| ARDELYX INC | ARDX | $1.3M | 263,168 | -0.03pp | 2q | +27.1%+$286.5K | |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | $1.3M | 38,069 | +0.26pp | 6q | +15.1%+$167.0K | |
| SERIES PORTFOLIOS TR | CLOZ | $1.3M | 47,807 | -0.06pp | 12q | HELD | |
| CULLINAN THERAPEUTICS INC | CGEM | $1.3M | 69,182 | +0.46pp | 2q | +185.9%+$819.1K | |
| JOHNSON & JOHNSON | JNJ | $1.3M | 4,922 | -0.06pp | 19q | HELD | |
| VERA THERAPEUTICS INC | VERA | $1.1M | 26,000 | -0.03pp | 6q | HELD | |
| ORCHESTRA BIOMED HLDGS INC | OBIO | $1.1M | 253,651 | -0.06pp | 5q | HELD | |
| SPRUCE BIOSCIENCES INC | SPRB | $1.1M | 20,000 | - | new | NEW | |
| CONNECT BIOPHARMA HLDGS LTD | CNTB | $1.1M | 444,862 | -0.05pp | 3q | +14.7%+$135.7K | |
| ISHARES TR | IBB | $1.0M | 5,500 | flat | 5q | HELD | |
| BIOGEN INC | BIIB | $864.2K | 4,000 | +0.02pp | 4q | HELD | |
| PFIZER INC | PFE | $778.7K | 32,337 | -0.13pp | 19q | HELD | |
| APPLE INC | AAPL | $721.7K | 2,494 | flat | 19q | HELD | |
| CANADIAN NAT RES LTD MED TER | CNQ | $663.6K | 16,800 | -0.14pp | 19q | HELD | |
| PELTHOS THERAPEUTICS INC | PTHS | $623.8K | 22,073 | +0.07pp | 4q | +4.7%+$28.3K | |
| INTERNATIONAL BUSINESS MACHS | IBM | $602.4K | 2,142 | +0.01pp | 14q | HELD | |
| MICROSOFT CORP | MSFT | $596.8K | 1,600 | -0.04pp | 19q | HELD | |
| VERASTEM INC | VSTM | $592.1K | 155,000 | -0.02pp | 2q | +49.0%+$194.8K | |
| KURA ONCOLOGY INC | KURA | $578.9K | 52,767 | +0.05pp | 4q | HELD | |
| SOLID BIOSCIENCES INC | SLDB | $561.5K | 56,208 | +0.09pp | 6q | +19.2%+$90.6K | |
| 36614N201 | $511.0K | 3,767 | - | new | NEW | ||
| INSMED INC | INSM | $453.5K | 4,253 | - | new | NEW | |
| LB PHARMACEUTICALS INC | LBRX | $420.8K | 12,965 | - | new | NEW | |
| CAREDX INC | CDNA | $388.5K | 13,630 | - | new | NEW | |
| Q32 BIO INC | QTTB | $387.4K | 30,412 | - | new | NEW | |
| ENLIVEN THERAPEUTICS INC | ELVN | $313.8K | 6,183 | - | new | NEW | |
| RYMAN HOSPITALITY PPTYS INC | RHP | $308.5K | 2,400 | +0.03pp | 19q | HELD | |
| BROADCOM INC | AVGO | $268.2K | 710 | +0.01pp | 17q | HELD | |
| KIMBERLY-CLARK CORP | KMB | $263.4K | 2,400 | flat | 19q | HELD | |
| NVIDIA CORPORATION | NVDA | $256.1K | 1,280 | flat | 17q | HELD | |
| BOSTON SCIENTIFIC CORP | BSX | $256.1K | 6,000 | - | new | NEW | |
| WAVE LIFE SCIENCES LTD | WVE | $232.4K | 40,000 | -0.05pp | 6q | HELD | |
| RAIN ENHANCEMENT TECHNOLOGIE | RAIN | $210.5K | 101,686 | -0.04pp | 2q | HELD | |
| MONDELEZ INTL INC | MDLZ | $173.5K | 3,000 | -0.01pp | 4q | HELD | |
| QUANTA SVCS INC | PWR | $126.7K | 176 | +0.01pp | 10q | HELD | |
| BRISTOL-MYERS SQUIBB CO | BMY | $115.2K | 2,000 | -0.43pp | 6q | -85.3%-$669.7K | |
| EASTERN BANKSHARES INC | EBC | $111.2K | 5,000 | flat | 14q | HELD | |
| ALPHABET INC | GOOGL | $107.2K | 300 | +0.01pp | 17q | HELD | |
| LEGACY HOUSING CORP | LEGH | $105.1K | 4,000 | +0.01pp | 19q | HELD | |
| CORTEVA INC | CTVA | $102.1K | 1,206 | -0.01pp | 19q | HELD | |
| ISHARES TR | IWP | $101.8K | 695 | flat | 3q | HELD | |
| UNITED RENTALS INC | URI | $88.4K | 78 | +0.01pp | 17q | HELD | |
| INVIVYD INC | IVVD | $87.2K | 100,000 | -0.03pp | 4q | HELD | |
| AMAZON COM INC | AMZN | $71.5K | 300 | flat | 17q | HELD | |
| DANAHER CORP DEL | DHR | $34.3K | 180 | flat | 17q | HELD | |
| DOW HLDGS INC | DOW | $33.0K | 1,206 | -0.01pp | 19q | HELD | |
| FS KKR CAP CORP | FSK | $30.2K | 2,875 | - | new | NEW | |
| BRIGHTSTAR LOTTERY PLC | BRSL | $26.8K | 2,500 | flat | 2q | HELD | |
| BLACKSTONE INC | BX | $24.7K | 210 | flat | 17q | HELD | |
| UNITEDHEALTH GROUP INC | UNH | $23.7K | 57 | flat | 17q | HELD | |
| OCCIDENTAL PETE CORP | OXY | $22.8K | 469 | -0.01pp | 19q | -29.3%-$9.4K | |
| THERMO FISHER SCIENTIFIC INC | TMO | $22.6K | 45 | flat | 17q | HELD | |
| SALESFORCE INC | CRM | $12.1K | 77 | flat | 17q | HELD | |
| STARWOOD PPTY TR INC | STWD | $6.6K | 400 | flat | 19q | HELD | |
| KYNDRYL HLDGS INC | KD | $4.8K | 428 | flat | 14q | HELD | |
| OCCIDENTAL PETE CORP | OXYWS | $4.3K | 194 | - | new | NEW | |
| GE HEALTHCARE TECHNOLOGIES I | GEHC | $3.2K | 50 | flat | 11q | HELD | |
| WABTEC | WAB | $1.6K | 6 | flat | 19q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $94.8M | 50.1% |
| Software & IT Services | $33.0M | 17.5% |
| Capital Markets | $28.3M | 15.0% |
| Banks & Lending | $9.6M | 5.1% |
| Other sectors | $8.7M | 4.6% |
| Not classified | $14.7M | 7.8% |
What the disclosed book did
This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.
| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +15.6% | +14.8% | +0.8% | 94% |
| Q1 2026 | +10.0% | -4.6% | +14.7% | 100% |
| Q4 2025 | +14.7% | +2.4% | +12.3% | 98% |
| Q3 2025 | +14.3% | +7.8% | +6.5% | 97% |
| Q2 2025 | +7.0% | +10.5% | -3.4% | 100% |
| Q1 2025 | -18.4% | -4.6% | -13.8% | 97% |
| Q4 2024 | +12.3% | +2.1% | +10.1% | 86% |
| Q3 2024 | +6.6% | +5.4% | +1.1% | 70% |
Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $189.2M | 84 | 11 | 16 | 4 | 12 | 62.8% | 43 |
| Q1 2026 | $168.0M | 85 | 10 | 17 | 13 | 12 | 60.5% | 44 |
| Q4 2025 | $215.9M | 87 | 13 | 15 | 20 | 14 | 70.7% | 43 |
| Q3 2025 | $248.0M | 88 | 15 | 15 | 9 | 12 | 69.9% | 43 |
| Q2 2025 | $220.6M | 85 | 10 | 15 | 13 | 9 | 71.6% | 42 |
| Q1 2025 | $212.0M | 84 | 15 | 10 | 14 | 20 | 73.0% | 42 |
| Q4 2024 | $276.5M | 89 | 8 | 8 | 11 | 11 | 77.5% | 43 |
| Q3 2024 | $284.6M | 92 | 9 | 9 | 22 | 16 | 68.0% | 44 |
| Q2 2024 | $250.6M | 99 | 9 | 17 | 9 | 16 | 68.5% | 43 |
| Q1 2024 | $282.8M | 106 | 12 | 16 | 10 | 19 | 64.4% | 44 |
| Q4 2023 | $261.6M | 113 | 15 | 13 | 8 | 34 | 74.5% | 44 |
| Q3 2023 | $261.9M | 132 | 15 | 11 | 9 | 31 | 67.8% | 44 |
| Q2 2023 | $251.3M | 148 | 10 | 7 | 8 | 11 | 64.4% | 42 |
| Q1 2023 | $254.5M | 149 | 15 | 14 | 18 | 39 | 64.0% | 41 |
| Q4 2022 | $264.7M | 173 | 19 | 9 | 16 | 30 | 59.7% | 44 |
| Q3 2022 | $237.6M | 184 | 19 | 13 | 8 | 23 | 56.7% | 41 |
| Q2 2022 | $238.1M | 188 | 72 | 22 | 9 | 24 | 53.2% | 42 |
| Q1 2022 | $314.0M | 140 | 32 | 29 | 25 | 24 | 50.2% | 46 |
| Q4 2021 | $294.6M | 132 | 0 | 0 | 0 | 0 | 54.0% | 42 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.